Clinical Trials Directory

Trials / Unknown

UnknownNCT04389528

Evaluation of the Effect of tDCS on Cannabis Craving

Evaluation of the Effect of tDCS on Cannabis Craving: Multicentre Randomized, Double-blind Study Versus Placebo

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
78 (estimated)
Sponsor
Januel · Academic / Other
Sex
All
Age
18 Years – 63 Years
Healthy volunteers
Accepted

Summary

Cannabis is the most frequently consumed drug in France and its use continues to increase. Over the 18-64 age group as a whole, experimentation with cannabis at least once in a lifetime increased from 33% in 2010 to 42% in 2014, confirming the upward trend observed since the 1990. Cannabis, like all drugs, disrupts the reward circuit whose neurons originate in the ventral tegmental area and project into the mesolimbic and cortical structures. Acute cannabis use is thought to increase mesolimbic dopamine by affecting the Gabaergic or Glutamatergic system. Chronic cannabis use usurps the reward system and leads to changes in the mesolimbic circuit (nucleus accumbens, ventral tegmental area, amygdala, and prefrontal cortex), inducing increased craving, with persistent craving for the substance and vulnerability to relapse. Cognitively, addiction is associated with increased impulsivity, with a propensity to take risks leading to impaired decision-making. There is currently no validated drug treatment for cannabis addiction. Non-invasive brain stimulation could be an interesting therapeutic alternative.

Conditions

Interventions

TypeNameDescription
OTHERNeuromodulation by tDCSThe tDCS is a device for modulating cortical excitability. It consists of passing a low intensity direct electrical current over the scalp via two electrodes: an anode and a cathode soaked in a saline solution. Although there is a short-circuit effect through the scalp, a significant amount of electrical current enters the brain and changes the transmembrane potential.

Timeline

Start date
2018-09-17
Primary completion
2021-07-17
Completion
2021-12-17
First posted
2020-05-15
Last updated
2020-05-15

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04389528. Inclusion in this directory is not an endorsement.